Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCUR-101 with Androgen Directed Therapy in mCRPC
NCT04677855Phase 1Terminated
- Sponsor
- Pellficure Pharmaceuticals
- Start
- Mar 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of plumbagin in metastatic castration-resistant prostate cancer (mCRPC) (4 arms), sponsored by Pellficure Pharmaceuticals. Primary endpoint: Occurrence of Dose Limiting Toxicity at 28 days. Started Mar 2021; status: terminated.
02
Drugs
plumbagin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04677855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04677855.